文章摘要
李文英,张 锐,汪得喜,张 敏,曾 瑜,钟海波.血必净注射液联合胸腺肽α1对重症肺炎合并脓毒症患者血气指标、炎症因子及免疫功能的影响[J].,2021,(8):1502-1506
血必净注射液联合胸腺肽α1对重症肺炎合并脓毒症患者血气指标、炎症因子及免疫功能的影响
Effect of Xuebijing Injection Combined with Thymosinα1 on Blood Gas Indexes, Inflammatory Factors and Immune Function in Patients with Severe Pneumonia Complicated with Sepsis
投稿时间:2020-11-07  修订日期:2020-11-30
DOI:10.13241/j.cnki.pmb.2021.08.022
中文关键词: 血必净注射液  胸腺肽α1  重症肺炎合并脓毒症  血气指标  炎症因子  免疫功能
英文关键词: Xuebijing injection  Thymosinα1  Severe pneumonia complicated with sepsis  Blood gas index  Inflammatory factors  Immune function
基金项目:广东省医学科学技术研究基金项目(B2017100)
作者单位E-mail
李文英 广州市红十字会医院/暨南大学附属广州红十字会医院呼吸内科 广东 广州 510220 liwenying2381@163.com 
张 锐 广州市红十字会医院/暨南大学附属广州红十字会医院重症医学科 广东 广州 510220  
汪得喜 广州市红十字会医院/暨南大学附属广州红十字会医院呼吸内科 广东 广州 510220  
张 敏 广州市红十字会医院/暨南大学附属广州红十字会医院呼吸内科 广东 广州 510220  
曾 瑜 广州市红十字会医院/暨南大学附属广州红十字会医院呼吸内科 广东 广州 510220  
钟海波 广州市红十字会医院/暨南大学附属广州红十字会医院呼吸内科 广东 广州 510220  
摘要点击次数: 25
全文下载次数: 24
中文摘要:
      摘要 目的:探讨血必净注射液联合胸腺肽α1对重症肺炎合并脓毒症患者血气指标、炎症因子及免疫功能的影响。方法:回顾性分析2018年1月到2020年5月期间我院收治的150例重症肺炎合并脓毒症患者的临床资料,根据治疗方案的不同分为A组(血必净注射液治疗,n=75)和B组(血必净注射液联合胸腺肽α1治疗,n=75),两组均治疗10 d。对比两组疗效、常规疗效指标、血气指标、炎症因子及免疫功能,比较两组治疗期间不良反应情况。结果:B组治疗10 d后的临床总有效率为93.33%(70/75),高于A组的81.33%(61/75)(P<0.05)。B组28 d内机械通气时间、ICU治疗时间短于A组,急性生理学及慢性健康状况评分系统Ⅱ(APACHEⅡ)评分、快速序贯器官功能衰竭(SOFA)评分低于A组(P<0.05)。治疗10 d后,B组氧分压、血氧饱和度高于A组,二氧化碳分压低于A组(P<0.05)。治疗10 d后,B组超敏C反应蛋白(hs-CRP)、降钙素原(PCT)、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)低于A组(P<0.05)。治疗10 d后,B组CD3+、CD4+、CD4+/CD8+高于A组,CD8+低于A组(P<0.05)。两组不良反应发生率组间对比差异无统计学意义(P>0.05)。结论:血必净注射液联合胸腺肽α1治疗重症肺炎合并脓毒症患者,疗效确切且安全性较好,能改善患者血气状况,提高免疫功能,减轻炎症反应。
英文摘要:
      ABSTRACT Objective: To investigate the effect of Xuebijing injection combined with thymosinα1 on blood gas indexes, inflammatory factors and immune function in patients with severe pneumonia complicated with sepsis. Methods: The clinical data of 150 patients with severe pneumonia complicated with sepsis treated in our hospital from January 2018 to may 2020 were retrospectively analyzed. According to the different treatment schemes, they were divided into A group (Xuebijing injection, n=75) and B group (Xuebijing injection combined with thymosin α 1 treatment, n=75), both groups were treated for 10d. The curative effect, routine efficacy index, blood gas index, inflammatory factors and immune function were compared between the two groups. Results: The total effective rate of B group was 93.33% (70/75), which was higher than 81.33% (61/75) of A group (P<0.05). The mechanical ventilation time and ICU treatment time in B group were shorter than those in A group within 28 days, while acute physiology and chronic health score system Ⅱ (APACHE Ⅱ) score and rapid sequential organ failure (SOFA) score in B group were lower than those in A group (P<0.05). 10d after treatment, the oxygen partial pressure and blood oxygen saturation of B group were higher than those of A group, and the partial pressure of carbon dioxide was lower than that of group A(P<0.05). 10 d after treatment, the levels of high sensitivity C-reactive protein (hs-CRP), procalcitonin (PCT), interleukin-6 (IL-6), tumor necrosis factor -α (TNF-α) in B group were lower than those in A group (P<0.05). 10d after treatment, CD3+, CD4+, CD4+/CD8+ in B group were higher than those in A group, and CD8+ in B group was lower than that in A group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Xuebijing injection combined with thymosin α1 are effective and safe in the treatment of severe pneumonia complicated with sepsis, which can improve the blood gas status, improve the immune function and reduce the inflammatory reaction.
查看全文   查看/发表评论  下载PDF阅读器
关闭